Clinical Trials
6 trialsNCT04987203 2026-05-08
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 3 Completed
NCT03136627 2021-12-06
Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC
AVEO Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01297244 2020-10-27
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 2 Completed
NCT01673386 2020-10-27
TAURUS
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00502307 2020-09-01
A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 2 Completed
NCT00563147 2011-10-04
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 1 Completed